Researchers

WASHINGTON, March 31, 2016—Today’s Alzheimer’s disease drug pipeline, marred by more than a decade of high failure rates and public underinvestment, is offering near-term promise with 17 drugs on pace to launch in the next five years, according to a recent analysis conducted by ResearchersAgainstAlzheimer’s (RA2), an UsAgainstAlzheimer’s (UsA2) network. If only some of those drugs are successful in late-stage trials and cleared by the U.S. Food and Drug Administration (FDA), the potential innovations will be a much-needed stimulus to the goal of stopping America’s most costly disease, one that affects approximately 5.3 million Americans, a number that is expected to rise precipitously during the next few decades.    

Read the full letter online here

Plan needs funding

Editor: The Times-Tribune was right on target in its Dec. 27 editorial calling for U.S. leadership in the global effort to end Alzheimer's by 2025.

The United States is the global leader in drug development, and can catalyze leadership in funding innovative Alzheimer's research.

ResearchersAgainstAlzheimer’s Applauds Senate Appropriations Committee Approval of $84 Million Increase in Funding for NIA Alzheimer’s Research and $20 Million for Alzheimer’s Services and Supports

Researchers Call for More Rapid Growth in Research Funding to Achieve National Goal of Stopping Alzheimer’s by 2025

The July 4 news story “To revive his 2012 bid, Gingrich is finding his niches” highlighted a fundamental misunderstanding in American politics and culture today.

There’s nothing niche about Alzheimer’s, a cruel disease that afflicts one in three American families and one in eight Americans over age 65.

USAgainstAlzheimer's Calls on Political, Business, and Civic Leaders to Strengthen Support and Investment in Alzheimer's Research

Pages

^ Back to Top